Ubiquitin System: The Next Class of Drug Targets?
A Complex Role in Cellular Process & Growing Tool Set to Elucidate It
Bispecific Antibodies Close in on Cancer
Plotting Molecular Pincer Movements, Denying Cancer Room to Maneuver
Resolving Nonspecific Binding, Regeneration and Other Problems
Researchers Turn to Cloud Computing as Genomic Sequencing Data Threatens to Overwhelm Traditional IT Systems
Few to no drugs have emerged that impact either the cause or progression of diseases of the central nervous system. Early- and late-stage drug failures, mostly with small molecule drugs and the odd peptide, populate the neurodegenerative disease landscape. Companies have moved away from these types of drugs toward biologics like mAb therapeutics. Those that can successfully develop novel treatments, despite the formidable obstacles to drug development, have a lot to gain. The global market for neurodegenerative treatments will exceed $43.4 billion by 2015, Global Industry Analysts predict. Do you think there will be a breakthrough with mAbs?